Performance
psychiatryWith the Stocklytics Performance Screener, you have access to a wide range of performance metrics, enabling you to make informed decisions based on stock performance over different timeframes.
| name | arrow_downwardPERF. % 1W | PRICE | $ CHANGE | % CHANGE | PERF. % 1M | PERF. % 3M | PERF. % 6M | PERF. % YTD | PERF. % 5Y | PERF. % ALL TIME | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SMRNuScale Power Corporation | arrow_drop_up19.55% | $10.70 | $1.09 | arrow_drop_up11.34% | arrow_drop_up19.95% | arrow_drop_up12.51% | arrow_drop_up119.26% | arrow_drop_up240.76% | - | arrow_drop_down62.50% | AI Analysis | |||
CAPRCapricor Therapeutics | arrow_drop_up19.38% | $5.05 | $0.06 | arrow_drop_up1.20% | arrow_drop_up23.47% | arrow_drop_up6.09% | arrow_drop_down26.27% | arrow_drop_down1.36% | arrow_drop_up63.43% | arrow_drop_down98.87% | AI Analysis | |||
MRSNMersana Therapeutics | arrow_drop_up19.33% | $2.16 | -$0.03 | arrow_drop_down1.36% | arrow_drop_up64.88% | arrow_drop_up5.88% | arrow_drop_down55.37% | arrow_drop_down4.84% | arrow_drop_up23.42% | arrow_drop_down84.57% | AI Analysis | |||
GOSSGossamer Bio | arrow_drop_up19.31% | $1.05 | $0.09 | arrow_drop_up9.37% | arrow_drop_up12.95% | arrow_drop_up84.69% | arrow_drop_down22.22% | arrow_drop_up8.24% | arrow_drop_down95.22% | arrow_drop_down94.14% | AI Analysis | |||
OPRTOportun Financial | arrow_drop_up19.26% | $2.91 | $0.01 | arrow_drop_up0.34% | arrow_drop_down6.12% | arrow_drop_up5.81% | arrow_drop_up7.38% | arrow_drop_down24.61% | - | arrow_drop_down82.00% | AI Analysis | |||
CVRXCVRx | arrow_drop_up19.24% | $9.11 | -$0.14 | arrow_drop_down1.51% | arrow_drop_up5.56% | arrow_drop_down18.00% | arrow_drop_down56.39% | arrow_drop_down70.12% | - | arrow_drop_down67.46% | AI Analysis | |||
KWESWKWESST Micro Systems | arrow_drop_up19.20% | $0.01 | $0.00 | 0.00% | arrow_drop_down40.00% | arrow_drop_down63.92% | arrow_drop_down87.14% | - | - | arrow_drop_down99.92% | AI Analysis | |||
SONNSonnet BioTherapeutics Holdings | arrow_drop_up19.04% | $1.00 | -$0.04 | arrow_drop_down3.84% | arrow_drop_up38.88% | arrow_drop_down3.84% | arrow_drop_down51.69% | arrow_drop_down43.18% | - | arrow_drop_down99.99% | AI Analysis | |||
CARAvis Budget Group | arrow_drop_up19.02% | $85.90 | -$1.33 | arrow_drop_down1.52% | arrow_drop_down3.46% | arrow_drop_down23.14% | arrow_drop_down26.32% | arrow_drop_down51.09% | arrow_drop_up192.77% | arrow_drop_up2838.29% | AI Analysis | |||
SBFGSB Financial Group | arrow_drop_up18.95% | $20.40 | $1.64 | arrow_drop_up8.74% | arrow_drop_up34.56% | arrow_drop_up43.86% | arrow_drop_up46.34% | arrow_drop_up30.35% | arrow_drop_up27.88% | arrow_drop_up40.56% | AI Analysis | |||
CYBNCybin | arrow_drop_up18.82% | $9.18 | $0.62 | arrow_drop_up7.24% | arrow_drop_down8.49% | arrow_drop_down9.38% | arrow_drop_down42.48% | arrow_drop_down39.60% | - | arrow_drop_up597.86% | AI Analysis | |||
DYNTDynatronics | arrow_drop_up18.75% | $0.19 | $0.02 | arrow_drop_up18.54% | arrow_drop_up18.75% | arrow_drop_down44.03% | arrow_drop_down57.87% | arrow_drop_down67.54% | arrow_drop_down97.07% | arrow_drop_down99.67% | AI Analysis | |||
DRMADermata Therapeutics, Inc. Common Stock | arrow_drop_up18.66% | $1.78 | $0.03 | arrow_drop_up1.71% | arrow_drop_down11.88% | arrow_drop_down25.52% | arrow_drop_down70.33% | arrow_drop_down79.89% | - | arrow_drop_down65.70% | AI Analysis | |||
ADVW ADVWWAdvantage Solutions | arrow_drop_up18.65% | $0.02 | -$0.00 | arrow_drop_down1.96% | arrow_drop_up17.25% | arrow_drop_down17.63% | arrow_drop_down72.81% | arrow_drop_down65.86% | - | - | AI Analysis | |||
LPCNLipocine | arrow_drop_up18.62% | $4.84 | $0.07 | arrow_drop_up1.46% | arrow_drop_up32.96% | arrow_drop_down37.46% | arrow_drop_up14.42% | arrow_drop_up69.22% | arrow_drop_down90.07% | arrow_drop_down97.15% | AI Analysis | |||
TLISTalis Biomedical Corporation | arrow_drop_up18.58% | $1.85 | -$0.05 | arrow_drop_down2.63% | arrow_drop_down56.47% | arrow_drop_down78.73% | arrow_drop_down79.88% | arrow_drop_down76.99% | - | arrow_drop_down99.55% | AI Analysis | |||
MRNSMarinus Pharmaceuticals | arrow_drop_up18.57% | $1.66 | $0.06 | arrow_drop_up3.75% | arrow_drop_up23.88% | arrow_drop_up22.96% | arrow_drop_down81.63% | arrow_drop_down84.03% | arrow_drop_down70.97% | arrow_drop_down94.81% | AI Analysis | |||
QNCXCortexyme | arrow_drop_up18.53% | $0.86 | $0.10 | arrow_drop_up13.85% | arrow_drop_up41.85% | arrow_drop_up33.12% | arrow_drop_down24.75% | arrow_drop_down16.79% | - | arrow_drop_down97.36% | AI Analysis | |||
FCAPFirst Capital | arrow_drop_up18.52% | $38.00 | $3.46 | arrow_drop_up10.01% | arrow_drop_up20.99% | arrow_drop_up28.90% | arrow_drop_up39.29% | arrow_drop_up38.43% | arrow_drop_down37.43% | arrow_drop_up318.00% | AI Analysis | |||
TAOP TAOPTaoping | arrow_drop_up18.41% | $0.56 | -$0.00 | arrow_drop_down0.17% | arrow_drop_up6.15% | arrow_drop_down22.44% | arrow_drop_down48.73% | arrow_drop_down69.89% | arrow_drop_down98.33% | arrow_drop_down98.59% | AI Analysis |
Showing 161-180 of 4977
Results per page:
The Stocklytics Performance Screener ranks stocks by 1-week performance % in descending order, helping you identify the best-performing stocks over the past week. But we don’t stop there—our screener provides performance data across multiple timeframes to give you a comprehensive view of stock momentum.
Key performance metrics include:
- 1 Week % Performance – See which stocks delivered strong short-term gains.
- 1 Month % Performance – Track medium-term stock trends to spot emerging winners.
- 3 Month % Performance – Analyze quarterly performance for insights into longer-term trends.
- 6 Month % Performance – Gain a half-year view of stocks that have demonstrated sustained growth or resilience.
- 1 Year % Performance – Focus on long-term winners to identify potential long-term investments.
With the Stocklytics Performance Screener, you have access to a wide range of performance metrics, enabling you to make informed decisions based on stock performance over different timeframes.
Why Track Performance Across Multiple Timeframes?
- Short-Term Gains: Identify stocks with momentum that could indicate future growth opportunities.
- Long-Term Trends: Analyze long-term performers to focus on stocks with a proven track record.
- Diversified Analysis: Gain insights into both short-term fluctuations and long-term stability.
Discover the Power of Stocklytics Tools
Our suite of tools empowers you to make informed decisions, seize opportunities, and stay ahead in the competitive trading world.
See Stocklytics Tools